Feature|Articles|June 9, 2026

Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner

With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.

The pace and scale of the pharma industry’s turn toward China in early 2026 is difficult to overstate, with more than $43 billion in licensing commitments in just five months. What is currently unfolding can be described as a structural realignment of where the global drug industry sources its innovation, and its terms.

Related to this article

November 4th, 2026

Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie

Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.

October 26th, 2026

Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai

Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.

Lonza’s deal for five Merck KGaA sites would lift its U.S. network from four to nine, adding bioconjugate and viral vector capacity. Credit: Stock.Adobe.com/Murrstock

November 3rd, 2026

Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA

Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.

Teva adds infliximab-abda and etanercept-ykro to its U.S. biosimilar lineup, extending a Samsung Bioepis partnership that began with Epysqli in 2025. Credit: Stock.Adobe.com/KHAN VECTOR CO.

November 3rd, 2026

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva will gain U.S. rights to two approved Samsung Bioepis biosimilars in a profit-sharing deal expected to close by the end of 2026.

A planned Ayrmid merger would cut Karyopharm’s funded debt by about $141 million, subject to court approval and a market test of competing bids. Credit: Stock.Adobe.com/Vitalii Vodolazskyi

November 3rd, 2026

Karyopharm Enters Chapter 11 in Planned Merger With Ayrmid

Karyopharm filed for Chapter 11 under a plan to merge with Ayrmid, with competing bids allowed and closing targeted for the first quarter of 2027.

BioMarin pays $70 million upfront for a long-acting Fabry therapy, while Ferring agrees to acquire fertility biotech Gameto in a deal worth up to $1.38B. Credit: Stock.Adobe.com/Parradee

October 29th, 2026

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.

Astellas secures an option on Audax’s preclinical IL-12 fusion DAX-044 in a deal worth up to $1.34 billion; EVERSANA acquires HEOR firm Estima Scientific. Credit: Stock.Adobe.com/Yingyaipumi

October 28th, 2026

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.

Teva buys BioXcel’s BXCL501 and IGALMI through a bankruptcy sale, while Rumi Therapeutics takes an option on Enthorin’s Fragile X PDE2 inhibitor. Credit: Stock.Adobe.com/bas121

October 27th, 2026

Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin

Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.